SCHEMBL17895235

SCHEMBL17895235

CNc1nc2ccccc2n2c(-c3cc(OC)c(OC)c(OC)c3)cnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
IKBKB O14920 4/20 0.45
CHUK O15111 2/20 0.45
KDM4E B2RXH2 3/20 0.44
PAX8 Q06710 1/20 0.43
HTR2C P28335 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
EGFR P00533 1/20 0.41
LCK P06239 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895078 0.89 ADORA1 (0.46) MAPTIKBKBCHUKKDM4EPAX8
SCHEMBL19771243 0.87 IKBKB (0.46) IKBKBCHUKKDM4EHTR2CALDH1A1
SCHEMBL17895103 0.86 IKBKB (0.49) MAPTMEN1KMT2AIKBKBCHUK
SCHEMBL2816766 0.83 PDE2A (0.43) MAPTMEN1KMT2AIKBKBCHUK
SCHEMBL2817059 0.83 MAPT (0.47) MAPTMEN1KMT2AIKBKBCHUK
SCHEMBL2813904 0.83 PDE2A (0.49) IKBKBCHUKKDM4EHTR2CSMN1; SMN2
SCHEMBL17895220 0.82 IKBKB (0.49) IKBKBCHUKKDM4EHTR2CSMN1; SMN2
SCHEMBL2817762 0.82 IKBKB (0.47) MAPTMEN1KMT2AIKBKBCHUK
SCHEMBL30136943 0.82 IKBKB (0.47) MAPTMEN1KMT2AIKBKBCHUK
SCHEMBL2816677 0.82 HTR2C (0.51) MAPTMEN1KMT2AIKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP claimed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO claimed
CN-107454900-B Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer 蒙彼利埃大学 2020-08-07 CN disclosed
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP disclosed
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP disclosed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer NQO1, NQO2, ABL1 MAPT 4376/4885MEN1 599/4885KMT2A 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.